The two largest US pet specialty chains are about to turn veterinary clinics from a side project into a capital-allocation headline. The signals point to a specific outcome: by the end of March 2027, when Chewy and Petco report their fiscal fourth quarters, Chewy is likely to guide to at least 20 organically built Chewy Vet Care clinics for fiscal 2027 (roughly double its 2026 pace), and Petco is likely to put a number on 2027 Vetco Total Care hospital openings for the first time since it froze construction in 2024. Together that would be a combined pipeline of 25 or more new clinics, the first year since 2023 in which both chains add veterinary capacity at once.
This is not a breaking-news call. It rests on three things that happened between September 2 and September 16: Petco’s second-quarter call, Chewy’s second-quarter filing and the investor-conference commentary that followed it, and a small but telling acquisition in the veterinary software layer. Each is verifiable, each is dated, and each pushes in the same direction.
In short
- Prediction: by March 31, 2027, Chewy guides to 20 or more organic clinic openings for fiscal 2027 and Petco discloses a numbered 2027 hospital opening plan; combined pipeline of at least 25 new veterinary sites.
- Signal 1 (earnings and capex): Chewy’s 10-Q filed September 9 books Modern Animal at $399.8 million, funded by a first-ever $600 million term loan; management says two build teams “can build organically at two times the rate.”
- Signal 2 (earnings and capex): Petco’s September 2 call reported double-digit growth in pet visits and doctor days across roughly 300 hospitals and said the company will “begin to open additional vet hospitals in 2027.”
- Signal 3 (M&A in the picks-and-shovels layer): IDEXX bought CoVetAI on September 16, an AI ambient-scribe vendor, a bet that clinic throughput per veterinarian is about to matter more.
- Main caveat: Chewy’s CEO explicitly said the company is “not about to enter an investment cycle,” and Petco is still paying down $1.48 billion of debt; either could slow-walk the number.
Why this matters now
Pet retail spent 2025 and the first half of 2026 in a defensive crouch. Chewy trimmed its 2026 sales outlook in June as household pet formation cooled, Petco returned to positive comps only this spring, and Tractor Supply pulled back from its Petsense format. The category’s growth engine has shifted from new pets to more spend per pet, and the highest-margin place to capture that spend is the exam room.
That shift is why the clinic question is the one to watch. A retailer that owns the veterinary visit owns the prescription, the therapeutic diet recommendation, the insurance referral and the membership relationship. Chewy’s own math, disclosed at the Goldman Sachs conference on September 14, is that each mature clinic generates roughly $3.5 million of clinic revenue plus about $800,000 of attach sales back to Chewy.com. Petco’s math is similar in shape: hospital productivity now drives vet diet sales up double digits.
The timing also matters because both companies set 2027 capital plans between now and their Q4 calls. Chewy’s CEO Sumit Singh said on September 9 that the company has “not yet determined the appropriate levels of reinvestment for 2027.” Petco’s CEO Joel Anderson has said since June that hospital expansion is “on track to resume in 2027.” The next six months are when those two sentences become numbers.
Signal 1: Chewy’s 10-Q, its first term loan, and the “two times the rate” comment
Chewy reported fiscal Q2 2026 (the 13 weeks to August 2) on September 9. The headline numbers were steady: net sales of $3.33 billion, up 7.3 percent (5.7 percent excluding the SmartPak and Modern Animal acquisitions), Autoship at 84.6 percent of sales, 21.7 million active customers, and an adjusted EBITDA margin of 6.8 percent, up 90 basis points. Shares fell about 10 percent the same day on a free cash flow print of $89.5 million against $105.9 million a year earlier, per the company’s release.
The more interesting document is the 10-Q filed the same day. It discloses that the Modern Animal acquisition closed on May 21, 2026 at a purchase price of $399.8 million, of which $221.6 million is goodwill, $64 million is identified intangibles and $67.9 million is clinic property and equipment. It also shows long-term debt of $588.7 million against zero at the start of the year: Chewy entered a seven-year, $600 million senior secured term loan on June 23 at SOFR plus 175 basis points, its first term debt as a public company. The proceeds are described as available for general corporate purposes, but the sequencing (deal in May, loan in June, $400 million of buybacks in the first half) makes clear the balance sheet was reshaped to fund clinics and repurchases at the same time.
The operational disclosures matter more than the accounting. Modern Animal brought 29 clinics and over 100,000 member families, 40 to 50 percent of them new to Chewy, taking Chewy Vet Care from 18 locations to 47.
Management reiterated 10 to 12 organic openings for fiscal 2026 and a year-end footprint of about 60 clinics, with the combined network approaching $290 million of embedded revenue. Capex guidance stayed at 1.5 to 2 percent of sales, and the company still expects roughly 80 percent free cash flow conversion. We flagged the clinic economics as the number to watch in our Q2 preview, and the call delivered them: Chewy Vet Care again posted triple-digit revenue growth.
Then came the Goldman Sachs Global Consumer and Retail Conference on September 14. Singh described Chewy as “the largest de novo operator in the market,” said the Modern Animal deal would “immediately 2X our base,” and, in the sentence that anchors this piece, said that “two teams can build organically at two times the rate.” He also put per-clinic economics on the record: about $4.3 million of combined revenue per mature site, breakeven in roughly 20 months, and performance “20 to 30 percent better than industry averages.” If two build teams each sustain the 10-to-12 cadence Chewy has already demonstrated, the arithmetic lands at 20 to 24 organic openings a year.
What the filing does not say
The 10-Q gives no clinic-level capex split and no 2027 opening target. Singh was explicit that 2027 reinvestment levels are still being planned. The company also filed an automatic shelf registration on September 14 covering common stock, preferred stock and warrants, which is routine housekeeping for a company with a large sponsor holder but does give Chewy flexibility if it wants to fund a larger health acquisition with equity. Read together, the documents describe a company that has built the capacity to double its clinic cadence and has not yet committed to doing so.
Signal 2: Petco’s hospitals are finally productive enough to restart building
Petco reported fiscal Q2 2026 on September 2: net sales of about $1.5 billion, adjusted EBITDA of $122 million, and a second consecutive quarter of positive comparable sales. Full-year guidance was reaffirmed at flat to up 1.5 percent sales growth and $415 million to $430 million of adjusted EBITDA. Gross margin expanded 37 basis points to 39.7 percent, though CFO Sabrina Simmons noted that without a $6.8 million net tariff refund the rate was about flat.
The veterinary commentary is the signal. Petco operates roughly 300 wholly owned Vetco Total Care hospitals, a footprint it built aggressively between 2020 and 2023 and then froze: the company slowed new hospitals in April 2024 to protect free cash flow and opened none in 2026, instead working to “optimize” about 25 significantly underutilized locations. On the September 2 call, Anderson said Petco has “expanded doctor days by double digits,” reported “double-digit growth in total pet visits,” and, for the second quarter in a row, said the company plans to “begin to open additional vet hospitals in 2027.” Vet diet sales for both dogs and cats also grew double digits.
The balance sheet context explains why the restart is credible rather than aspirational. Petco made a voluntary $75 million debt prepayment on September 1, taking cumulative paydown over nine months to $170 million, with total debt down to $1.48 billion from $1.59 billion a year earlier. Capex is guided at approximately $140 million for the year “with a focus on return on invested capital,” and the company is guiding 15 to 20 net store closures. In other words, Petco is shrinking the box count while preparing to grow the hospital count, which is a deliberate reallocation, not a growth spurt.
The Petco Perks lesson
One more detail from the call is relevant to the prediction. Petco relaunched its membership program as Petco Perks in late January and was caught out when redemptions “far exceeded” projections, costing mid-single-digit millions in net sales before guardrails were added. Management now says peak redemptions are behind it and that personalization capabilities should show “positive impact in 2027.” A loyalty program that finally works is the connective tissue between a hospital visit and the next 12 months of food and pharmacy spend, the same logic we traced in the personalized-offers pattern at Target, Kohl’s and Lowe’s. Petco needs that plumbing working before it commits capital to new exam rooms, and the call suggests it now is.
Signal 3: IDEXX buys an AI scribe, and the throughput constraint becomes the story
On September 16, IDEXX Laboratories announced the acquisition of CoVetAI, a provider of AI-native ambient listening and clinical workflow software for veterinary practices. Terms were not disclosed. The press release describes CoVet as capturing and organizing information “from consultation to treatment planning and client follow-up,” reducing documentation burden and saving clinician time, and says the product will be integrated into the IDEXX software ecosystem while continuing to support third-party scribe tools.
Why does a diagnostics company’s tuck-in belong in a piece about retailer clinics? Because the binding constraint on any clinic rollout is not real estate, it is veterinarian hours. Petco’s own language, “doctor days,” is a throughput metric: hire more doctors and get more hours per doctor. Chewy’s claim that its clinics run 20 to 30 percent better than industry averages is a throughput claim.
When the dominant diagnostics and practice-software vendor spends money to raise minutes-per-visit productivity, it is telling you where its clinic customers expect to be constrained next year.
There is a second, more direct link. Chewy told the Goldman audience that its own B2B software is used by “half the veterinarians in the country,” about 18,000 practitioners. Chewy also disclosed that it expects AI-driven cost savings in the “low tens of millions” this year, scaling to approximately $50 million on an annualized basis in fiscal 2027, and it has an assistant in development for search and post-purchase service.
The vet software layer is consolidating around AI documentation at exactly the moment both chains are deciding how many rooms to build. That is not a coincidence; it is the industry preparing for more visits per doctor.
What the pattern suggests
Put the three signals side by side and a sequence emerges. Chewy has doubled its clinic base, borrowed to do it, and told investors it can now build at twice the prior rate. Petco has spent two years fixing hospital productivity, has reduced debt by $170 million, and has repeated on two consecutive calls that new hospitals restart in 2027.
The tooling layer is investing in per-doctor throughput. The pattern suggests both chains are preparing to guide to expansion, and the natural moment to do that is the Q4 call, when each company sets out its annual plan.
| Signal | Date | Source type | What it establishes | Direction |
|---|---|---|---|---|
| Chewy 10-Q and Q2 call | Sep 9, 2026 | SEC filing; earnings call | $399.8m Modern Animal price; $600m term loan; 47 clinics, 60 by year-end; capex 1.5–2% of sales | Capacity built, target not yet set |
| Chewy at Goldman Sachs | Sep 14, 2026 | Investor conference | “Two teams can build organically at two times the rate”; $4.3m revenue per mature clinic; 20-month breakeven | Pace can double |
| Petco Q2 call | Sep 2, 2026 | Earnings call | ~300 hospitals; visits and doctor days up double digits; “begin to open additional vet hospitals in 2027”; $170m debt paydown | Restart affirmed |
| IDEXX acquires CoVetAI | Sep 16, 2026 | Company press release | Diagnostics leader buys AI ambient scribe for vet practices | Throughput layer investing ahead of demand |
| Chewy Vet Care opens in Redmond, WA | Sep 18, 2026 | Local press | First Pacific Northwest clinic; rollout is national, not regional | Supporting |
Why the number is 20 for Chewy and “a number” for Petco
The two thresholds are set deliberately at different heights. Chewy has already disclosed a 10-to-12 organic cadence and has described a mechanism (two build teams) that doubles it, so a guide below 20 would mean management chose not to use capacity it says it has. Petco has been at zero openings for a full year and has framed 2027 as a restart, so the meaningful test is whether it discloses any numbered plan at all; a “handful” or “a small number” would be a partial hit.
We are not forecasting that Petco returns to its 2021–2023 pace of dozens per year. The balance sheet does not support that and management has not hinted at it.
| Scenario | Chewy FY2027 organic clinic guide | Petco 2027 hospital plan | Rough probability | Scoring |
|---|---|---|---|---|
| Base case: both expand | 20 or more | Numbered plan (any figure above zero) | ~50% | Full hit |
| Chewy leads, Petco waits | 20 or more | Qualitative only, or deferred to H2 2027 | ~20% | Partial hit |
| Measured pace | 13–19 | Numbered plan | ~15% | Partial hit |
| Margin first | 12 or fewer, or acquisition substitutes for build | No plan, further “optimization” | ~15% | Miss |
Wider context: the retailer-owned clinic has a mixed history
The idea of a retailer owning the medical visit is not new, and the precedents cut both ways. Banfield hospitals inside PetSmart stores, owned by Mars since 2007, remain the largest in-store veterinary network in the country and the template both Chewy and Petco are borrowing. On the human side, CVS’s MinuteClinic scaled to more than 1,000 sites, while Walgreens’ VillageMD venture expanded rapidly in 2021 and 2022 and then closed a large share of its clinics in 2024 after the unit economics failed to mature on schedule. Retailer clinics work when the visit feeds a high-frequency purchase cycle and fail when the clinic is a standalone cost center.
Pet care has a structural advantage over human primary care here: there is no third-party payer in the middle of most transactions, which means the retailer captures the full ticket and can price therapeutic diets and prescriptions into the relationship. Chewy’s claim that converting a customer to pharmacy adds $300 to $500 of net sales per active customer, and that fewer than half of its customers know it sells pharmacy at all, describes the opportunity precisely. The subscription economics that make Autoship work are the same ones that make a clinic visit worth more to Chewy than to an independent practice.
| Precedent | Peak scale | What happened | Lesson for 2027 |
|---|---|---|---|
| Banfield inside PetSmart (Mars) | ~1,000 hospitals | Durable for two decades; wellness plans drive retention | In-store vet works when membership is the product |
| Petco Vetco Total Care, 2020–2023 | ~300 hospitals | Built fast, then frozen in April 2024 to protect cash | Pace must match doctor supply, not real estate supply |
| Chewy Vet Care, 2024–2026 | 18 organic, then 47 with Modern Animal | Deliberate, economics-first; triple-digit growth | Small base, so doubling is achievable |
| Walgreens and VillageMD, 2021–2024 | Hundreds of co-located clinics | Rapid build, then mass closures and write-downs | Overbuilding ahead of demand is the failure mode |
The demand side is shifting toward cats and toward spend per pet
An industry survey reported in mid-September put US cat-owning households at about 53 million, and Petco’s Anderson noted that kitten-owning households have outnumbered puppy households since spring 2026. Cats visit the vet less often than dogs, which is a headwind for visit volume but a tailwind for the membership-and-telehealth model Modern Animal was built on. The demand backdrop, in other words, favors clinics that sell an annual relationship over clinics that sell walk-in visits, and both chains are building the former.
Implications for retailers, brands and investors
For pet specialty and mass retailers. The clinic race raises the bar for everyone who sells pet consumables without a medical relationship. Tractor Supply’s retreat from Petsense in July already showed how hard it is to compete in pet specialty on assortment alone.
Walmart and Amazon can match Chewy on price and delivery; neither currently owns exam rooms at scale. If the prediction lands, expect at least one of them to answer with a partnership rather than a build, most plausibly a telehealth or pharmacy tie-up, within 2027.
For pet food and pharma brands. Therapeutic diet and prescription volume is migrating to retailer-owned channels where the retailer, not the brand, controls the recommendation. Petco’s Hill’s fresh-food partnership launching in Q3 shows the shape of the accommodation: brands co-develop exclusives for the retailer’s clinic-adjacent shelf. Brands without a clinic relationship should expect to pay more, in retail media or in margin, for the same visibility.
For investors. The near-term tell is disclosure, not capex. We argued in August that retailers would start breaking out non-merchandise income as services and media outgrow the shelf. Chewy already reports clinic revenue growth qualitatively and says services are “not a significant component” of net sales; a 2027 opening target of 20 or more would likely be accompanied by the first quantified health-segment disclosure.
Petco reports services within a combined line. Watch for either company to add a clinic count or services revenue figure to its Q4 release; that is the leading indicator that the number is coming.
Checkpoints before March
- Chewy Q3 (early December 2026): confirm year-end clinic count of about 60 and whether management pre-announces a 2027 range. Any mention of a third build team or a second clinic acquisition would move the base case up.
- Petco Q3 (early December 2026): look for the phrase “hospital openings” with a number attached, and for any change to the 15-to-20 net store closure guide. A further debt prepayment before year-end would strengthen the restart case.
- Chewy Q4 (late March 2027) and Petco Q4 (mid-March 2027): the scoring events. The prediction is scored on the guidance given on those calls and in the accompanying releases.
Caveats: what could go wrong
Chewy’s own words argue against a step-change. At the same Goldman session that produced the “two times the rate” line, Singh said, “We are not about to enter an investment cycle,” and stressed that Chewy can “self-fund a majority of these investments” while continuing to expand margins. Capex guidance of 1.5 to 2 percent of sales is unchanged.
A management team that has spent two years rebuilding investor trust on margin discipline, with the stock down roughly a third this year, could reasonably choose 14 to 16 clinics and call it acceleration. That would be a partial hit, not a full one.
Petco’s balance sheet still binds. $1.48 billion of debt and about $122 million of annual net interest expense leave little room. Anderson’s framing was “continuous improvement,” not acceleration, and the company is closing 15 to 20 stores this year. A plausible alternative is that Petco announces hospitals inside its new store format rather than a standalone opening count, which would make the prediction harder to score cleanly.
Veterinarian supply is the hard constraint. Both companies’ expansion math assumes they can staff new rooms. Petco’s doctor-days metric is improving, and Chewy’s clinics are reportedly above industry productivity, but the national shortage of veterinarians has not been resolved, and every new site competes for the same graduates. If either company reports rising clinic labor costs in Q3, the 2027 guide is likely to be conservative.
Consumer demand could soften further. Chewy’s guidance explicitly assumes no “meaningful consumer recovery,” and Petco’s comps are positive but barely. A weaker holiday quarter would push both toward preserving cash. The clinic model is more resilient than discretionary hard goods, but it is not immune.
Acquisition could substitute for construction. Chewy said it will “opportunistically evaluate M&A” in health and now has a shelf registration and a term loan in place. If Chewy buys another regional group instead of building, the organic guide could stay near 12 even as the footprint grows. The prediction is framed on organic openings precisely to test whether the “two teams” mechanism is real; an acquisition-led year would be a miss on the letter of the forecast even if the strategic direction is confirmed.
FAQ
What exactly is being predicted, and by when?
By March 31, 2027, on or alongside their fiscal Q4 earnings calls, Chewy guides to 20 or more organically built Chewy Vet Care clinics for fiscal 2027, and Petco discloses a numbered plan for 2027 Vetco Total Care hospital openings. The combined implied pipeline is 25 or more new veterinary sites.
How many clinics does Chewy have today?
Per the September 9 call and 10-Q, Chewy Vet Care had 18 organic locations before the Modern Animal deal closed on May 21, 2026; Modern Animal added 29, taking the network to 47. Management guided to roughly 60 by the end of fiscal 2026, with 10 to 12 organic openings this year. A Redmond, Washington clinic opened on September 18.
Why did Petco stop building hospitals?
Petco slowed new hospital construction in April 2024 to protect free cash flow after a rapid build to roughly 300 locations, and opened none in 2026 while optimizing about 25 underutilized sites. On its September 2 call the company said it will “begin to open additional vet hospitals in 2027,” citing double-digit growth in pet visits and doctor days.
Isn’t the Modern Animal deal old news? It was announced in April.
The agreement was announced in April and closed in May, but the purchase price ($399.8 million), the goodwill allocation and the $600 million term loan that sits behind it were only disclosed in the 10-Q filed September 9. The “two teams, two times the rate” framing came at the Goldman conference on September 14. Both are within the window this piece covers, and both change what the deal implies for 2027.
Chewy’s CEO said the company is not entering an investment cycle. Doesn’t that contradict the prediction?
It is the strongest counter-signal, and it is why the base case is roughly 50 percent rather than higher. Our reading is that “not an investment cycle” refers to the margin trajectory (capex staying at 1.5 to 2 percent of sales) rather than to clinic count. Twenty clinics at Chewy’s disclosed cost per site fits comfortably inside that capex envelope on $13.5 billion of sales. If management instead holds the organic count near 12, the prediction is scored a miss.
Why does an IDEXX software deal count as a signal?
Because veterinarian hours, not leases, are the constraint on clinic growth. IDEXX buying an AI ambient-scribe vendor on September 16 is the diagnostics and practice-software leader investing to raise visits per doctor. It is independent of both retailers and points the same way: the industry expects more clinic capacity to be needed in 2027.
Could Walmart or Amazon build clinics instead?
Neither has disclosed a plan to own veterinary hospitals at scale, and both have the option of partnering with existing chains or telehealth providers. Our expectation is a partnership response rather than a build, and it is outside the scope of this prediction. A Walmart or Amazon clinic announcement would, if anything, raise the pressure on Chewy and Petco to guide higher.
What would a partial hit look like?
Chewy guiding to 13 to 19 organic clinics with a numbered Petco plan, or Chewy at 20-plus with Petco offering only qualitative language. Either would confirm the direction but not the magnitude. A miss is Chewy at 12 or fewer organic openings (or an acquisition substituting for construction) combined with Petco deferring again.
How will this be scored?
On the fiscal Q4 earnings releases and call transcripts for both companies, expected in mid-to-late March 2027. Interim checkpoints are the Q3 calls in early December 2026. Any later restatement of clinic counts will be noted but the score will rest on the guidance as originally given.